NL-OMON21892招募中不适用
Immune intervention with tolerogenic dendritic cells in type 1 diabetes. A phase 1 safety study called D-sense
eiden Universitu Medical Center0 个研究点目标入组 9 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 9
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Age 18-50 years;
- •Diagnosis of type 1 Diabetes Mellitus at least 18 months (dated from the first insulin injection);
排除标准
- •Use of immunosuppressive or immunomodulatory therapies, including systemic steroids within 1 month prior to
- •enrolment and/or prior monoclonal antibody therapy of any type given for any indication at any time;
研究者
相似试验
招募中
不适用
Immune intervention with tolerogenic dendritic cells in type 1 diabetes. A phase 1 safety study called D-sensediabetestype 1 diabetes10018424NL-OMON50354eids Universitair Medisch Centrum9
尚未招募
不适用
Dendritic cell-based immunotherapy combined with low-dose cyclophosphamide in patients with malignant pleural mesotheliomamesothelioma10035597NL-OMON32554Erasmus MC, Universitair Medisch Centrum Rotterdam10
已完成
不适用
Dendritic cell-based immunotherapy for ovrian cancer patients.NeoplasmsKCT0000831Asan Medical Center10
招募中
不适用
Tolerogenic dendritic cell therapy for rheumatoid arthritis.1000381610023213rheumatoid arthritisNL-OMON55219niversitair Medisch Centrum Utrecht18
已完成
1 期
The feasibility of dendritic cell-based immunotherapy targeting synthesized long peptides containing helper epitopes for malignant tumor.JPRN-UMIN000014435Medical Corporation Isokai Seren Clinic Tokyo10